# Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)

> **NCT00092742** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 4086 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MK0663, etoricoxib
- **DRUG:** Comparator: Diclofenac sodium

## Key facts

- **NCT ID:** NCT00092742
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 4086 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092742, "Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00092742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*